209 results
Page 7 of 11
424B5
6hksq0scm sndo86azd
27 Jul 12
Prospectus supplement for primary offering
12:00am
424B3
wo5u iywf7th
26 Jul 12
Prospectus supplement
12:00am
SC TO-T/A
EX-99
55tj2qftcoz j6
23 Jul 12
Third party tender offer statement (amended)
12:00am
8-K
EX-2.1
mfiel4i68qp6lroqr73
3 Jul 12
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
qd66ypmde94eag
26 Jan 12
Net Sales Rise 7% to $5.5 Billion in Fourth Quarter
12:00am
8-K
EX-99.1
qjaom
9 Jan 12
Bristol-Myers Squibb to Acquire Inhibitex
12:00am
8-K
EX-99.1
mnogtpgb wxx3s
27 Oct 11
Bristol-Myers Squibb Delivers Strong Third Quarter with Important Clinical Data, Solid Operating Results and Continued Focus on Business Development
12:00am
8-K
EX-10.1
dxiim
4 Oct 11
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
vil25givwu 0j
27 Jan 11
Receives U.S. Regulatory Approval for KOMBIGLYZE™ XR, and First-Line Indication for SPRYCEL® in Fourth Quarter
12:00am
8-K
EX-99.1
hci3m89r319xm1u
10 Sep 10
Bristol-Myers Squibb to Acquire ZymoGenetics
12:00am
SC TO-C
c293bove qh0xlz2dvfi
8 Sep 10
Information about tender offer
12:00am
SC TO-C
sczjke
7 Sep 10
Information about tender offer
12:00am
8-K
EX-99.1
o5oheea6
22 Jul 10
Bristol-Myers Squibb Second Quarter Featured Robust Clinical Data
12:00am